blocked adhesion to osteopontin, suggesting that integrins mediate Arg-Gly-Asp-dependent adhesion. Indeed, an antibody against the a,183 integrin neutralized adhesion of both endothelium and smooth muscle cells to osteopontin by :=50%, demonstrating that a,f3 is one osteopontin receptor on vascular cells. Osteopontin also promoted the migration of smooth muscle cells in a Boyden-type chamber, with halfmaximal effects observed at 77 nmol/L osteopontin. Checkerboard analysis demonstrated that this stimulus was chemotactic in nature. Our findings suggest that osteopontin may be functionally important as an adhesive and chemotactic molecule for vascular cells, particularly when levels of osteopontin are dramatically increased, as is the case after arterial angioplasty and in atherosclerotic plaques. (Circ Res. 1994;74:214-224.) 
Abstract Osteopontin is an Arg-Gly-Asp-containing acidic phosphoprotein recently shown to be upregulated in vascular smooth muscle during rat arterial neointima formation and in human atherosclerotic plaques. Functional studies showed that osteopontin promoted adhesion of both cultured aortic endothelial cells and aortic smooth muscle cells. Adhesion of vascular cells to osteopontin was dose dependent and half maximal when solutions containing 7 and 30 nmol/L osteopontin were used to coat wells for endothelial and smooth muscle cells, respectively. Smooth muscle cells adherent to osteopontin were spread after 60 minutes, whereas endothelial cells remained round, although flattened, at this time point but were spread at 90 minutes. Cell spreading on osteopontin was accompanied by the formation of focal adhesion plaques. A newly developed anti-osteopontin antibody completely inhibited adhesion of both cell types to osteopontin but not to fibronectin or vitronectin. In addition, the peptide GRGDSP orphogenic processes are thought to contrib-M/l ute significantly to vascular pathologies such as restenosis and atherosclerosis, as well as to the normal ontogenic development of the vasculature.' It is clear from studies of both endothelial cells and smooth muscle cells (SMCs) that proteins with cell adhesive properties may play key roles in mediating these events. Several examples are the growth effects of thrombospondin on both SMCs and endothelium, the contribution of laminin to in vitro angiogenesis,2 phenotypic changes in vascular SMCs plated on laminin or fibronectin substrates,3 and stimulation of endothelial cell migration with fibronectin.4 Thus, the ability of a molecule to provide an adhesive substrate for vascular cells may suggest a broad range of functions pertaining to cellular remodeling.
In a previous study, we discovered the expression of osteopontin, a secreted adhesive glycoprotein, in vascular SMCs by use of a differential cloning strategy aimed at identifying genes that would distinguish the phenotypically distinct SMC types we have observed in vitro. 5 Subsequently, we showed that endothelial denudation of either the rat aorta or carotid artery caused a dramatic increase in osteopontin mRNA and protein synthesis selectively in SMCs forming the arterial neointima. 6 The spatial and temporal pattern of osteopon-tin expression coincided with alterations in SMC phenotype, invasion of the intima, and proliferation, thus implicating a role for osteopontin in the early events leading to vascular remodeling and neointima formation in this model. The potential relevance of osteopontin expression in the progression of human vascular disease was further suggested by the focal expression of osteopontin in atherosclerotic plaques but not normal arteries. 6 Although osteopontin was originally identified as a matrix protein in bone, the protein has subsequently been found in kidney, inner ear, brain, placenta, decidua, bone marrow, a variety of epithelial cell surfaces, and tumor cells. 7 The roles of osteopontin in these various tissues have not been clearly elucidated, although adhesion is one postulated function, since osteopontin contains a highly conserved attachment motif Arg-Gly-Asp (RGD) similar to that found in other adhesive matrix molecules that interact with cellular integrins.8 This idea has been supported by in vitro studies of bone, ligament, and transformed cells, where RGD-dependent attachment and spreading are promoted by osteopontin.8-11 Furthermore, osteopontin expression correlates with the metastatic potential of tumor cells, implicating osteopontin in processes controlling cellular invasiveness. 12 In the present study, we have investigated whether osteopontin can provide an adhesive substrate for SMCs and endothelial cells, two cell types important in vascular remodeling processes. Additionally, we have tested the effects of osteopontin on the migration of smooth muscle cells, since this is a commonly proposed function for osteopontin that, nev-ertheless, has never before been directly demonstrated. Our results indicate that both cell types can adhere and spread on osteopontin in an RGD-dependent fashion with the contribution of the a,83 integrin receptor and that osteopontin is a potent chemotactic molecule for vascular SMCs. These findings suggest a potential role for osteopontin in vivo in situations of vascular injury involving adhesive and migratory processes.
Materials and Methods

Matrix Components and Chemicals
Human vitronectin (Sigma Chemical Co, St Louis, Mo) was resuspended in phosphate-buffered saline (PBS) to a concentration of 0.5 mg/mL and stored frozen until use. Human fibronectin was purchased from GIBCO, Grand Island, NY, and stored frozen until use. Cycloheximide was purchased from Sigma and, before use, was diluted in ethanol to a concentration of 25 mg/mL. This solution was further diluted to a working concentration of 25 ,g/mL.
RGD Peptides and Anti-a4v Antibody
Synthetic peptides of the sequence GRGDSP and GRGESP were obtained from GIBCO (formerly Telios), resuspended in PBS at 10 mg/mL, and stored frozen until use. LM609, a neutralizing a,833 antibody, was generously provided by Dr David Cheresh, Scripps Research Institute, La Jolla, Calif. An immunoglobulin fraction was purified from the ascites on protein A, desalted, and equilibrated against PBS.
Cell Culture
Bovine aortic endothelial cells (BAECs) were isolated from bovine aortas and characterized as previously described.13 BAECs were maintained in Waymouth's complete medium containing 0.23% sodium bicarbonate, 0.35 mg/mL L-glutamine, 1 mmol/L sodium pyruvate, and 0.01 mmol/L nonessential amino acids supplemented with 10% fetal bovine serum and 100 U/mL each of penicillin and streptomycin (all from GIBCO). SMCs were isolated from 12to 15-day-old (pup) or 3-month-old (adult) Wistar-Kyoto rats as previously described.14 Both neonatal and adult rat SMC cultures were maintained in Waymouth's complete medium supplemented with 5% calf serum and 100 U/mL penicillin and streptomycin. Human aortic medial SMCs (HNb 18) were derived from a newborn infant autopsy specimen obtained from Dr Joe Siebert, Children's Hospital, Seattle, Wash, by use of a collagenase/elastase digestion method15 and cultured in Waymouth's complete medium containing 20% fetal bovine serum. Cells derived in this fashion were judged to be SMCs by immunofluoresence staining with an anti-smooth muscle a-actin-specific antibody (SM-1, Sigma). Cells were fed twice weekly and passaged at confluence. Cells were maintained in a humidified incubator at 37°C with 5% CO2. Cultures between passages 4 and 7 (for BAECs), 15 and 20 (for rat SMCs), and 4 and 8 (for human SMCs) were used for experiments.
Purification of Osteopontin
Serum-free medium conditioned for 48 hours by pup rat aortic SMC cultures was collected, dialyzed against PBS, and fractionated over a DEAE-Sepharose column. Anionic proteins eluted between 0.4 and 0.6 mol/L NaCl were collected and adsorbed to barium citrate by adding 1/10 vol of 0.61 mol/L barium chloride and 1/10 vol of 0.13 mol/L sodium citrate to samples. The precipitate was washed with water and eluted into 0.2 mol/L sodium citrate. Proteins were then quantified using a Micro BCA protein assay kit and analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. The protein was judged to be >95% pure by Coomassie and silver staining of the gel and N-terminal sequence analysis.
N-Terminal Sequencing
N-terminal sequencing was carried out by the University of Washington Molecular Pharmacology Facility, Seattle, using an Applied Biosystems model 477A liquid-phase protein sequencer with an on-line model 120A phenylthiohydantoin analyzer.
Osteopontin Antibody
A goat was immunized with 50 ,ug rat osteopontin protein with Freund's complete adjuvant to produce antibody OP199. Osteopontin was purified as described above but with an additional reverse-phase purification step involving high-pressure liquid chromatography over a Vydac C4 column. This preparation was judged to be highly purified (>99% pure) on the basis of Coomassie and silver staining as well as N-terminal sequence analysis. Three booster injections of 50 ,tg each in Freund's incomplete adjuvant were administered 3 weeks apart after the initial immunization. The first test bleeds were obtained 6 weeks after the initial injection and then after the following 3 weeks. Serum was purified over protein G capsules (Amicon, Beverly, Mass) to collect an IgG fraction. This fraction was dialyzed, sterile-filtered, and stored frozen. Specificity was tested by enzyme-linked immunosorbent assay, Western blot analysis, and inhibition studies in functional assays and for cross recognition of vitronectin and fibronectin. 
Western Blot Analysis
Conditioned medium was collected from confluent cultures of neonatal (pup) rat SMCs in serum-free medium and concentrated by use of Centricon-30 columns, and 1/250 of the total fraction was used in the blots probed with antibody OP199. Samples were boiled for 2 minutes, diluted 1:1 with sample buffer containing 100 mmol/L Tris (pH 6.8), 10% SDS, 10% glycerol, 0.1% bromophenol blue, and 5% ,B-mercaptoethanol, and separated on a 10% SDS-polyacrylamide gel under reducing conditions. The proteins were blotted onto Zeta Probe membranes (Bio-Rad Laboratories, Richmond, Calif) overnight and incubated at room temperature as follows. Nonspecific binding was blocked by 10% nonfat dry milk with 2% normal rabbit serum for 1 hour, followed by either anti-osteopontin (1:1000 dilution for OP199) or normal goat IgG (at a dilution required to obtain the same concentration as OP199) with 1% normal rabbit serum for 2 hours. Blots were incubated for 1 hour with 1:400 dilution of biotinylated rabbit anti-goat IgG (Vector Laboratories, Burlingame, Calif). Peroxidase labeling was carried out with an avidin-peroxidase complex (ABC Elite, Vector Laboratories) as per the manufacturer's instructions, using 4-chloro-1-naphthol as a substrate. Prestained molecular weight standards were used to estimate protein size (Bio-Rad Laboratories).
Adhesion Assay
Test adhesive substrates were diluted in PBS to stated concentrations, and 50 ,uL per well was added to 96-well Maxisorp plates (Nunc, Naperville, Ill) and placed overnight at 4°C. Using radioiodination of osteopontin, vitronectin, and fibronectin, we have determined the amounts of each protein bound to the wells under these conditions (see the Table) . After the coating period, wells were rinsed with PBS, and nonspecific binding sites were blocked with 10 mg/mL bovine serum albumin (BSA) at 37°C for 1 hour. Cells were detached by minimal trypsinization (1 to 2 minutes), placed immediately into an equal volume of 0.5 mg/mL soybean trypsin inhibitor (STI, Sigma), and centrifuged. The cell pellet was washed with STI and repelleted by centrifugation. Cells were resuspended in Waymouth's complete medium with I mg/mL BSA. Approximately 30 000 cells were placed in each well and allowed to adhere at 37°C for 30 to 90 minutes. In experiments in which RGD peptides or antibodies were used, they were added to wells immediately before cells. In studies with OP199, the antibody was allowed to interact with protein-coated wells for 30 minutes before the addition of cells. Nonadherent cells were rinsed off with PBS, and the remaining cells were fixed with 4% paraformaldehyde for 5 minutes. Cells were stained with 0.5% toluidine blue in 4% paraformaldehyde for 5 minutes and rinsed in water. Cells were solubilized with the addition of 100 gL of 1% SDS and quantified in a microtiter plate reader at 595 nm. For direct quantification of adherent cells, plates were rinsed, trypsinized, and counted in a Coulter counter. Experiments described were performed in quadruplicate and repeated a minimum of three times. Mean±SEM data from representative experiments are shown.
Immunocytochemistry
For actin staining, cells were fixed with 4% paraformaldehyde at room temperature for 15 minutes, permeabilized with acetone for 3 minutes, and stained with 2 U of Bodipy 503/512 phallacidin (Molecular Probes, Inc, Eugene, Ore). For vinculin staining, cells were fixed in 4% paraformaldehyde at room temperature for 15 minutes and permeabilized for 2 minutes with 0.2% Triton X-100 in 50 mmol/L Tris (pH 7.5). Monoclonal anti-vinculin clone (VIN-11-5, Sigma) was used at a 1:60 dilution and incubated for 1 hour, followed by fluorescein-conjugated rabbit immunoglobulin to mouse immunoglobulins (DAKO, Carpinteria, Calif) in a 1-hour incubation. All slides were mounted with Vectashield mounting media (Vector Laboratories).
Migration Assay
Test substances were diluted to appropriate concentrations in Waymouth's complete medium containing 200 jig/mL BSA rat SNIC rat bone hunman bovine porcine niurine L P V K V A E F G S S E E K A * * * * * * * * * * * * * * * I * * * Q * DS * * * * * * Q * * * * P T N S * * * * * * Q * * * * QT N S * * * * * * L * * * * *tTD1)St * * * * * L FIG 1. Comparison of osteopontin N-terminal sequences. Osteopontin purified from the conditioned medium of rat smooth muscle cell (SMC) cultures had an identical deduced and actual N-terminal sequence as osteopontin purified from rat bone. 8, 16 The deduced N-terminal sequences of human,1718 bovine,19 porcine,20 anid murine (deduced and actual are identical)21.22 osteopontin are shown. The determined N-terminal sequence of osteopontin from human bone differs from the predicted sequence in the underlined residues,23 where a glutamic acid replaces the serine and a glutamine replaces the glutamic acid. and placed in the bottom wells of a modified Boyden chemotaxis chamber (Neuro Probe Inc, Cabin John, Md), unless otherwise indicated. A polycarbonate filter with 8-gm pores was placed between the test proteins and the upper chamber. Identical results were obtained when filters precoated with collagen type I (Vitrogen, Celtrix Laboratories, Palo Alto, Calif) were used. Freshly trypsinized rat aortic SMCs were washed twice and resuspended in Waymouth's media containing 200 gg/mL BSA. Fifty thousand cells were placed in the top wells and allowed to migrate for 4 to 6 hours at 37°C in a humidified chamber. After the incubation period, cells that had migrated to the bottom of the filter were fixed with methanol and stained with hematoxylin. Migration was quantified by cell counts of three random x400 high-power fields in each well. Each experiment was performed in quadruplicate and repeated at least twice.
Results
Purification of Osteopontin
Osteopontin was purified from the conditioned medium of pup rat SMC cultures. N-terminal sequencing of this preparation detected a sequence that was identical to that of osteopontin purified from rat bone (Fig 1) . This preparation was further analyzed by gel electrophoresis and Western blot analysis with two different antibodies made against rat osteopontin. Graphs showing quantification of adhesion assays with cell counts vs cell staining. Wells were coated with fibronectin solutions ranging in concentration from 0.45 to 1 13 nmol/L. Bovine aortic endothelial cells were allowed to adhere in wells for 60 minutes. Parallel groups of quadruplicates were quantified one of two ways: (1) adherent cells were fixed, stained with 0.5% toluidine blue, washed, and solubilized with 1 % sodium dodecyl sulfate, and absorbance was read at 595 nm in a microtiter plate reader (a); and (2) plates were rinsed, and adherent cells were trypsinized with 0.05% trypsin and counted in a Coulter counter (b). Values represent means and standard error. Mean absorbance was plotted against total cell number from the same experiment, and a simple curve shows a close to linear relation between the two methods of quantification (c). molecular weight species (>100 kD), similar to results seen by others.22'24 It has generally been the idea that the very acidic nature of osteopontin, as well as the presence of variable posttranslational modifications, has led to anomalous migration in SDS-polyacrylamide gels and therefore to reports of different molecular weights for osteopontin. Although the higher molecular weight forms have been recognized by others working with osteopontin from different sources,22,24 it is not clear if these are oligomeric complexes of osteopontin or if we are detecting associations of osteopontin with other proteins. The lower molecular weight species may be a degradation product or a processed osteopontin fragment. 25 26 A second anti-osteopontin antibody, OP199, made against purified rat osteopontin was raised in the goat in an attempt to generate a neutralizing antibody. This antibody recognized rat osteopontin by an enzymelinked immunosorbent assay (data not shown) and recognized by Western blot analysis purified rat osteopontin in a pattern similar to the monoclonal antibody (Fig 2c) without cross-reacting with vitronectin or fibronectin. In addition, antibody OP199 recognized only proteins with molecular weights identical to that of osteopontin in a crude aliquot of rat pup SMC-conditioned medium (Fig 2c, lane CM) .
Quantification of Adhesion Assay
Parallel adhesion assays compared two methods of quantification: (1) staining of the cells with toluidine blue and quantifying adhesive cells by absorbance at 595 nm or (2) direct cell counting of adherent cells. Fibronectin has been described as a molecule that promotes the adhesion and spreading of endothelial cells, and thus initial experiments tested BAEC adhesion to fibronectin as a validation of our staining method of quantification. Fig 3 shows the results of an adhesion curve either (1) quantified by staining and absorbance measurements or (2) counted with a Coulter counter. The maximal number of adherent cells at 60 minutes was 75% of the cells plated per well. The two quantification methods generated similar curves, and when the results of each method were plotted against each other, the relation was linear (Fig 3c) with a correlation coefficient (R2) of .96. Thus, the amount of stain taken up by the adhered cells is proportional to the actual number of cells present, and this is a valid measurement of adherent cells in our assay.
Adhesion of Vascular Endothelial Cells to Osteopontin
BAECs adhered to wells coated with substrates of osteopontin, fibronectin, and vitronectin in a dosedependent manner (Fig 4a) . Fibronectin and vitronectin were used as adherent substrates on the basis of previous reports of their ability to promote endothelial cell adhesion.27 Dose-dependent adhesion was observed when solutions containing up to 100 nmol/L osteopontin were used to coat microtiter wells. Half-maximal effects were observed using coating solutions containing 7 nmol/L osteopontin (0.45 ,g/mL), 11 nmol/L fibronectin (2.5 ,ug/mL), and 7 nmol/L vitronectin (0.49 ,ug/mL). The adherent cells were firmly attached but appeared rounded at 30 to 60 minutes of incubation and began to spread at 75 minutes. BAECs were highly spread after 90 minutes of incubation and formed a monolayer at 120 minutes (Fig 4b) . The time course of adhesion and spreading on osteopontin was identical to that of cells plated on either fibronectin or vitronectin substrates (not shown). Cells plated in control wells with only BSA present did not adhere and were washed off during the rinses.
Active protein synthesis was not necessary for the adhesion of BAECs to osteopontin (Fig 4b, photomi crograph d), since pretreatment of cultures with 25 ,ug/mL cycloheximide for 2 hours and maintenance of the drug during the assay period did not diminish adhesion of the cells. Maximal adhesion to osteopontin was obtained at 90 minutes, when 80% of BAECs were adherent and 76% of cycloheximide-treated BAECs had adhered to the substrate. These results indicate that ongoing synthesis of other proteins is not responsible for BAEC adhesion to an osteopontin substrate. In addition, since interactions of cells with matrix proteins often leads to organization of the cytoskeleton, we tested whether such an organization would occur in cells plated on osteopontin. Cells adherent to osteopontin representative experiment in which quadruplicates are plotted as mean+SEM. Wells containing only bovine serum albumin were used as blanks to set the zero point. b, For photomicrographs a through c, wells were coated with 100 nmol/L solutions of OP or contained 10 mg/mL BSA (control), and bovine aortic endothelial cells were allowed to adhere for the time points indicated. Nonadherent cells were rinsed off with phosphate-buffered saline, and photographs were taken (original magnification x200). For photomicrograph d, cultures were maintained in 25 gg/mL cycloheximide (CHX) for 2 hours before and during the assay. Cells were plated into wells precoated with 100 nmol/L OP, and after 60 minutes, they were rinsed and photographed as above. For photomicrograph e, bovine aortic endothelial cells were incubated for 2 hours in wells precoated with 100 nmol/L OP, rinsed, and fixed for immunocytochemistry. Actin was visualized using fluorescein-conjugated phallicidin. For photomicrograph f, cells were treated as above and stained with a monoclonal antibody against VN and then with a fluorescein-conjugated rabbit anti-mouse antibody (original magnification x400). Arrows indicate vinculin in focal contacts.
were fixed and stained with either fluorescein-conjugated phallicidin (binds only to filamentous actin; Fig  4b, photomicrograph e) or a monoclonal antibody to vinculin (Fig 4b, photomicrograph f) . At 60 minutes, BAECs were still rounded on an osteopontin substrate, and the actin staining was faint and perinuclear with the absence of filamentous organization. BAECs adherent to osteopontin and allowed to spread organized their actin filaments and formed focal contacts, as demonstrated by the localization of vinculin to discrete contact areas within the cell. These findings were similar to cells that had been pretreated with cycloheximide before and during experiments.
Adhesion of Vascular SMCs to Osteopontin
Adult rat aortic SMCs were also tested for their ability to adhere to substrates of osteopontin compared with other extracellular matrix proteins. Pretreatment of cultures and maintenance of cycloheximide in the assay did not significantly decrease adhesion or spreading of SMCs (Fig 5b, photomicrograph d ). The number of SMCs adherent to osteopontin was lower than that to substrates of fibronectin or vitronectin at 60 minutes, indicating either that there are fewer osteopontin receptors on these cells or that complete binding equilibrium did not occur at 60 minutes. In fact, we found that the maximal number of adherent cells occurred at 2 hours and was 80% of the total input of SMCs and 73% of the total in cycloheximide-treated cultures. It is also a possibility that not all of the SMCs in our cultures contain identical receptor profiles. Cytoskeletal organization was also assessed after SMC adhesion to osteopontin by immunocytochemistry using fluorescein-conjugated phallicidin (interacts only with filamentous actin) or an antivinculin antibody. At early times, such as 30 minutes into the assay when SMCs were not well spread on osteopontin, the actin staining showed faint perinuclear localization and an absence of filaments. Fig 5b ( photomicrographs e and f) shows that, in SMCs spread on an osteopontin substrate, actin filaments were detectable and vinculin was localized to punctate areas near the cell periphery. The same results were observed with SMCs that had been treated with cycloheximide. (FN) . a, Rat smooth muscle cells at 30 000 cells per well were allowed to adhere for 60 minutes to wells that had been coated overnight with solutions of OP, FN, and VN ranging from 1 through 200 nmol/L. This is a representative experiment in which quadruplicates are plotted as mean-+-SEM. Wells containing only bovine serum albumin were used as blanks to set the zero point. b, For photomicrographs a through c, rat smooth muscle cells were incubated in wells coated previously with 100 nmol/L OP for the time points indicated. Nonadherent cells were rinsed off with phosphate-buffered saline, and photographs were taken (original magnification x200). For photomicrograph d, cultures were maintained in 25 gg/mL cycloheximide (CHX) for 2 hours before and during the assay. Cells were plated into wells precoated with 100 nmol/L OP, and after 60 minutes, they were rinsed and photographed as above. For photomicrograph e, smooth muscle cells were incubated for 2 hours in wells precoated with 100 nmol/L OP, rinsed, and fixed for immunocytochemistry. Actin was visualized using a fluorescein-conjugated phallicidin. For photomicrograph f, cells were treated as above and stained with a monoclonal antibody against vinculin and then with a fluorescein-conjugated rabbit anti-mouse antibody (original magnification x400). Arrows indicate vinculin in focal contact.
Antagonists of Endothelial and SMC Adhesion to Osteopontin
The antibody to osteopontin, OP199, was tested for its ability to block endothelial and SMC adhesion to substrates of osteopontin, vitronectin, and fibronectin. This was in contrast to the effects of 200 gg/mL normal goat IgG, which did not affect BAEC adhesion to osteopontin. Adhesion to substrates of vitronectin and fibronectin were not inhibited at any dose of OP199 antibody. Antibody OP199 strongly inhibited interaction of rat SMC with osteopontin substrates (Fig 6b) . A concentration of 50 gg/mL inhibited 86% adhesion, and 100 gg/mL inhibited 96% SMC adhesion to osteopontin. These effects were specific, since OP199 did not reduce SMC adhesion to substrates of vitronectin or fibronectin and 100 jzg/mL normal goat IgG had no effect.
Synthetic hexamer peptides corresponding to the sequences GRGDSP and GRGESP were used to test the importance of the osteopontin RGD sequence in mediating cell attachment. Fig 7a shows that BAEC adhesion to osteopontin was inhibited with 100 Mmol/L RGD hexamer peptide with significant inhibition seen with 10 gmol/L peptide, very similar to GRGDSP competition seen on fibronectin and vitronectin substrates (data not shown). The RGD peptide was also able to inhibit SMC adhesion to osteopontin at a concentration of 100 gmol/L (Fig 7b) . Similar inhibition was seen with SMC adhesion to fibronectin and vitronectin (data not shown).
The concentrations of GRGDSP used to inhibit adhesion are typical of studies in which RGD-containing peptides are used to compete for RGD-dependent integrin binding. In contrast, even very high concentrations (.500 gmol/L) of the GRGESP peptide showed only partial inhibitory activity in either cell type. These results suggested that the cellular receptor for osteopontin on vascular cells might be an integrin molecule, and other researchers have provided evidence that the a/33 integrin is an osteopontin receptor.2'-31 Therefore, we used a neutralizing monoclonal antibody against a133, LM6097 to test whether this receptor mediated osteopontin interaction with endothelium and SMCs. Fig   8a shows that LM609 blocked 45% BAEC adhesion to osteopontin. Since LM609 does not functionally neutralize rat act33, we tested a human SMC line that adhered to osteopontin in a manner similar to that found with rat SMCs. LM609 was also able to partially block the adhesion of human SMCs to osteopontin (Fig 8b) , and the interaction was completely blocked by OP199. As expected, adhesion of these cells to vitronectin was inhibited by LM609 and not affected by OP199. Inhibition of both cell types to osteopontin was only partially neutralized by (FN) . The antibody was incubated at 370C for 30 minutes before the additions of bovine aortic endothelial cells (a) and rat smooth muscle cells (b) at 30 000 cells per well. The assay was stopped after 60 minutes, and percent adhesion was calculated as the percentage of control groups to which no antibody was added. Control groups were treated identically with the same concentrations of normal goat IgG.
LM609 even at concentrations of 100 ,ug/mL purified LM609 IgG (not shown). The result of LM609 only partially inhibiting adhesion to a vitronectin substrate is consistent with the probable presence of multiple vitronectin receptors, including a,I5 and a,31.
The interaction of BAECs with osteopontin also led to clustering of a,83 receptors, demonstrated by immunocytochemical localization with LM609 (Fig 8c) . One hour after adhesion to osteopontin, a,f3 was distributed in a punctate pattern near the periphery of BAEC cell borders, indicating formation of focal contacts and cellular organization on an osteopontin substrate. The pattern of a,P3 localization was similar to that found in areas enriched with vinculin. Cells were also stained with normal mouse IgG as a control or without a primary antibody, and no specific immunofluorescence was noted (not shown).
Osteopontin Effects on SMC Migration
We functionally characterized osteopontin further by testing for effects on SMC migration using a Boydentype chamber assay. Osteopontin stimulated the dosedependent migration of rat vascular SMCs as shown in Fig 9a. Half-maximal effects were observed with 77 nmol/L osteopontin. To determine whether the migratory stimulus was chemotactic or chemokinetic in nature, the location of osteopontin in the migration chamber was varied. A chemotactic effect was noted, since a gradient of osteopontin (Fig 9b, bottom only) neutralizing antibody against av,83. Cell adhesion was assayed after 60 minutes. b, Human smooth muscle cells were plated into wells that had been previously coated with either OP or vitronectin (VN) with either 200 gg/mL OP199 (199) or 50 ,ug/mL LM609. Assay time was 60 minutes. c, Bovine aortic endothelial cells were allowed to adhere for 60 minutes to glass slides precoated with a substrate of OP, at which time nonadherent cells were rinsed off with phosphate-buffered saline, and cells were fixed with 4% paraformaldehyde. After methanol permeabilization, cells were stained with a 1:50 dilution of LM609 followed by a 1:30 dilution of fluorescein-conjugated anti-mouse lgG. Arrows indicate avP3 localized in focal contacts.
also chemotactic for rat SMCs in this assay, in agreement with previous results. 33 The specificity of the migratory effect was determined by inhibition with anti-osteopontin antibody, OP199, but not with normal goat IgG (Fig 9c) . OP199 was not a general inhibitor of migration, since it had no effect on the migration of rat vascular SMCs to the potent chemotactic agent, platelet-derived growth factor (data not shown).
Discussion
We report that purified smooth muscle-derived osteopontin was able to promote adhesion of both vascular SMCs and endothelial cells in culture via an RGDmediated interaction with at least one integrin, a433. Furthermore, osteopontin was shown to be chemotactic for SMCs. In addition, we describe the preparation and characterization of an antibody against osteopontin, OP199, which effectively and specifically neutralized the adhesive and migratory effects of osteopontin on these cell types. Our studies are the first to demonstrate that osteopontin is an adhesion molecule for vascular endothelium and SMCs and a chemotactic factor for vascular SMCs. Our findings suggest that osteopontin may share some functions with other proteins, such as collagen types I and III, laminin, fibronectin, and vitronectin in endothelial cells27 and laminin, fibronectin, vitronectin, and collagen types I and IV in smooth muscle,3334 all known to function as adhesive substrates and, in some cases, migratory stimuli for vascular cells.
Our studies are in general agreement with previous work characterizing osteopontin as an RGD-dependent adhesive molecule for a variety of cell types.35-37 Most recently, Brown et a124 showed that osteopontin could facilitate adhesion of human intestinal SMCs in an RGD-dependent manner, but the receptor responsible for this interaction was not determined. In vascular SMCs and endothelial cells, as well as osteoclasts, the integrin ca433 appears to be one receptor for osteopontin binding (the present study and Reference 31). However, in our experiments, an anti-cavr3 antibody, LM609, only partially inhibited SMC and BAEC binding to osteopontin, whereas an RGD-containing hexamer completely abolished the adhesive interaction. These data suggest that other integrin-like molecules might alse be important for binding of vascular cells to osteopontin. Clearly, determining whether other integrins are involved in osteopontin binding to vascular cells as well as other cell types is a high priority and might shed some light on the roles of osteopontin in diverse tissues.
Whereas a migratory potential has been widely postulated for osteopontin on the basis of its overexpression in metastatic cells,38 its ability to stimulate macrophage accumulation after peritoneal injection in mice,39 and its presence in actively remodeling bone,40 no data directly supporting this idea have been previously reported. Our studies using the modified Boyden chemotaxis chamber show that purified osteopontin could stimulate smooth muscle migration in a dose-dependent manner, with half-maximal effects observed at 77 nmol/L osteopontin. In contrast, using a similar chemotaxis system, migration of gingival fibroblasts to osteopontin was not observed at concentrations as high as 20 pg/mL.35 This discrepancy no doubt reflects differences in the effects of osteopontin on the different cell types used in each study, since gingival fibroblasts, like vascular smooth muscle, showed enhanced attachment to osteopontin. The differences in function of osteopontin in various cell types might depend on the complement of different receptors or signaling pathways prevalent in a given cell type.
The adhesive and migratory properties of osteopontin in vascular cells observed in the present study suggest a potential role for this molecule in the morphogenic events seen during vascular development or repair. After balloon angioplasty, for example, SMCs undergo phenotypic, proliferative, and migratory changes resulting in the formation of a smooth muscle-rich neointimal lesion41,42 similar to that seen in many vascular pathologies in humans. Indeed, we recently showed that osteopontin protein and mRNA levels were dramatically elevated after arterial balloon angioplasty in rat carotid arteries and aortas6 and [antibodyl uglml FIG 9. Graphs showing chemotactic effects of osteopontin (OP) on smooth muscle cells. a, Dose-response curve is shown for rat aortic smooth muscle cell migration to smooth muscle-derived OP. Cells migrated per x400 high power field (cells/HPF) are given as mean±SD for a representative experiment performed in quadruplicate. b, Checkerboard analysis of smooth muscle cell migration to OP is shown. Ten micrograms per milliliter OP (154 nmol/L) or 4 ,ug/mL vitronectin (VN, 57 nmol/L) were either omitted (neither) or added to the top, bottom, or top and bottom Boyden chamber compartments, and smooth muscle cells were allowed to migrate for 6 hours. Mean±SD values were determined as in a. c, Migration of smooth muscle cells to 7.5 j.g/mL OP (115 nmol/L) was assessed in the presence of increasing concentrations of antiosteopontin antibody, OP199, or normal goat lgG. Results are given as mean±SD cells/HPF for a representative experiment performed in quadruplicate.
in the human atherosclerotic plaque. In contrast, normal adult arteries contained very little osteopontin. Furthermore, basic fibroblast growth factor, transforming growth factor-f, and angiotensin II, all implicated in the arterial injury response, induced osteopontin mRNA and protein levels in cultured vascular SMCs.6 It is interesting to note that other molecules appearing in the vascular cell microenvironment after injury, ie, fibrinogen, von Willebrand factor, fibronectin, elastin, and thrombospondin, also promote adhesion and organization of vascular cells.2,27 Many of these adhesive proteins interact with cells via integrin receptors, which can mediate adhesion and migration of both SMCs and endothelial cells. A second category of proteins expressed after arterial injury includes those that are antiadhesive or mediate cell detach-ment from matrix factors. Examples of these proteins are tenascin,43 generally considered an antiadhesive molecule, and a number of proteases hypothesized to facilitate cell migration by releasing cells from their matrixes. 44 The de novo production of an adhesive protein substrate may be a prerequisite for cellular responses to injury, and it is likely that a balance of adhesion and deadhesion are necessary for processes such as invasion and migration.
Our findings suggest the following hypothetical model for osteopontin regulation and function during arterial neointimal formation: Endothelial injury stimulates the release of vasoactive factors (basic fibroblast growth factor, transforming growth factor-p,B platelet-derived growth factor, angiotensin II, and no doubt others) from platelets and endothelial and medial SMCs, initiating changes, proliferation, and migration in medial SMCs. Some of these molecules, in addition, upregulate osteopontin expression. Osteopontin then works in combination with proteases, integrins, and other matrix molecules to promote adhesion and facilitate movement of SMCs into the intimal compartment. In this scenario, osteopontin would simultaneously favor the reendothelialization of the wound by acting as an adhesive substrate (and possibly migratory stimulus?) for endothelial cells. Effects of osteopontin on SMCs and endothelial cells would thus be synergistic in promoting arterial repair. Other hypotheses also exist, none of which are mutually exclusive. For example, osteopontin may be critical for maintenance of the distinct phenotypes of SMCs seen in vascular lesions, as suggested by its differential expression in phenotypically distinct cultured SMCs.545 Alternatively, osteopontin may be involved in some way in cell cycle progression, as suggested by the studies of Gadeau et al. 46 Experiments using the specific neutralizing antibody against osteopontin (OP199) will allow us to directly test these various hypotheses in vivo in the rat balloon injury model and are currently in progress.
